Stock Scorer

Design Therapeutics, Inc. (DSGN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. Every figure as a table ›

Revenue Quarterly

0 50K 100K 150K Q1 '20: 142K Q2 '20: 31K Q3 '20: 20K Q4 '20: 33K Q1 '25: 0 Q2 '25: 0 Q3 '25: 0 Q4 '25: 0 Q1 '26: 0 Q2 '26: 0 Q2 '20 Q4 '20 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -11.3M Q4 '21: -11.1M Q1 '22: -13.4M Q2 '22: -15.6M Q3 '22: -19.2M Q4 '22: -19.4M Q1 '23: -21.7M Q2 '23: -22.6M Q3 '23: -18.8M Q4 '23: -15.1M Q1 '24: -14.4M Q2 '24: -15M Q3 '24: -16.2M Q4 '24: -16.7M Q1 '25: -20.4M Q2 '25: -21.6M Q3 '25: -19.3M Q4 '25: -18.2M Q1 '26: -19.7M Q2 '26: -22.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '21: -11.3M Q4 '21: -11.1M Q1 '22: -13.3M Q2 '22: -15M Q3 '22: -17.7M Q4 '22: -17.3M Q1 '23: -19.3M Q2 '23: -19.9M Q3 '23: -15.8M Q4 '23: -11.8M Q1 '24: -11.1M Q2 '24: -11.8M Q3 '24: -13M Q4 '24: -13.7M Q1 '25: -17.7M Q2 '25: -19.1M Q3 '25: -17M Q4 '25: -16M Q1 '26: -17.6M Q2 '26: -20.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -8.2M Q4 '21: -9.2M Q1 '22: -11.8M Q2 '22: -10.5M Q3 '22: -13.9M Q4 '22: -15.1M Q1 '23: -17.4M Q2 '23: -13.8M Q3 '23: -14.5M Q4 '23: -12.8M Q1 '24: -12.4M Q2 '24: -11.3M Q3 '24: -9.5M Q4 '24: -9.9M Q1 '25: -16.8M Q2 '25: -14.4M Q3 '25: -11.2M Q4 '25: -12M Q1 '26: -16.4M Q2 '26: -15.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-18M -12M -6M 0 6M 12M 18M Q3 '21: -9.1M Q4 '21: -9.6M Q1 '22: -11.9M Q2 '22: -10.7M Q3 '22: -14.2M Q4 '22: -15.4M Q1 '23: -17.5M Q2 '23: -13.9M Q3 '23: -14.6M Q4 '23: -12.8M Q1 '24: -12.6M Q2 '24: -11.4M Q3 '24: -9.6M Q4 '24: -9.9M Q1 '25: -16.9M Q2 '25: -14.5M Q3 '25: -11.2M Q4 '25: -12M Q1 '26: -16.4M Q2 '26: -15.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '21: 55.1M Q3 '21: 55.2M Q1 '22: 55.5M Q2 '22: 55.7M Q3 '22: 55.8M Q1 '23: 55.9M Q2 '23: 55.9M Q3 '23: 56M Q1 '24: 56.5M Q2 '24: 56.6M Q3 '24: 56.6M Q1 '25: 56.8M Q2 '25: 56.9M Q3 '25: 57M Q1 '26: 61.4M Q2 '26: 62.5M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.50 -1.00 -0.50 0.00 0.50 1.00 1.50 Q3 '21: -1.01 Q4 '21: -0.86 Q1 '22: -0.79 Q2 '22: -0.92 Q3 '22: -1.03 Q4 '22: -1.14 Q1 '23: -1.25 Q2 '23: -1.34 Q3 '23: -1.30 Q4 '23: -1.20 Q1 '24: -1.05 Q2 '24: -0.90 Q3 '24: -0.85 Q4 '24: -0.88 Q1 '25: -0.99 Q2 '25: -1.12 Q3 '25: -1.19 Q4 '25: -1.22 Q1 '26: -1.20 Q2 '26: -1.18 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

Not drawn for DSGN: Gross Profit, Cost of Revenue. Nothing in this filer's XBRL supports them for the periods asked for. That is a gap in the filing, not a zero, and drawing a flat line would be an invention.